Clinical Trial News

Early research indicates CBD may help prevent or treat COVID-19, but clinical trials are needed. Studies show CBD can block virus replication in cells and mice, yet THC negates CBD's effects. High doses of CBG and CBDA prevent virus entry into cells, but safety for humans is unclear. Ongoing trials aim to determine CBD's efficacy in COVID-19 treatment.

EDAP TMS S.A. has published positive pre-clinical results in the journal Cancers, showcasing the potential of intraoperative high intensity focused ultrasound (HIFU) ablation for treating locally advanced pancreatic adenocarcinoma (LAPA). This study represents a significant step towards developing a clinical treatment for LAPA, a condition with a less than 5% five-year survival rate.

Maze Therapeutics secures $190M financing to advance nine precision medicine programs and its Compass platform for genetically defined diseases. MZE001 for Pompe disease expected to enter clinical trials in H1 2022. Andy Tran joins board. Funding supports rare and common disease treatments, including Pompe, chronic kidney disease, and ALS.

The Research Ethics Board at Sunnybrook Research Institute has approved an amendment to the CATCO trial protocol to include LSALT Peptide, a drug candidate by Arch Biopartners Inc., for treating organ damage caused by inflammation, in a new arm of the trial. The next step is seeking Health Canada's approval before dosing begins.

LimmaTech Biologics AG received FDA Fast Track designation for LBT-SA7, a vaccine targeting Staphylococcus aureus infections, aiming to expedite its development. LBT-SA7, designed to prevent SSTIs by neutralizing toxins, will undergo Phase 1 trials in the U.S. with results expected in 2025.

Hutchison China MediTech Limited (Chi-Med) announced that the U.S. FDA has granted Fast Track Designation to fruquintinib for treating metastatic colorectal cancer (mCRC) patients who have undergone prior chemotherapy and biological therapy. This designation aims to expedite the development and review of fruquintinib, which has shown promise in improving overall survival in mCRC patients.

Faricimab treatment for nAMD showed improved or stabilized visual acuity and reduced retina thickness in a large study. Patients extended injection intervals while maintaining disease control. Faricimab targets VEGF and angiopoietin-2, potentially offering greater efficacy and reduced systemic risks compared to anti-VEGF-only treatments.

BTX-A treatment showed efficacy in 52% of TN-MS and 45% of TN-P patients. Efficacy was higher with concomitant continuous pain and lower with prior interventional treatments.

HUTCHMED announces the NDA for ORPATHYS® and TAGRISSO® combination for EGFR mutation-positive NSCLC with MET amplification has been accepted by China's NMPA, triggering a milestone payment from AstraZeneca. The SACHI trial supports the NDA, showing improved PFS. HUTCHMED and AstraZeneca aim to enhance NSCLC treatment continuity and quality of life.

A study on 61 subjects with primary immunodeficiency evaluated the efficacy, pharmacokinetics, and safety of IGSC 20% for IgG replacement. The SBI rate was 0.017 per person per year, with a 99% upper confidence limit of 0.036. Mean trough IgG concentrations were comparable to previous regimens. Seven subjects had serious TEAEs, none drug-related. IGSC 20% was well tolerated, with a safety profile similar to IGIV-C 10%.